A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Latest Information Update: 05 Jun 2025
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors Apellis Pharmaceuticals
Most Recent Events
- 30 May 2025 Planned End Date changed from 1 Oct 2027 to 1 Jun 2028.
- 30 May 2025 Planned primary completion date changed from 1 Oct 2027 to 1 Jun 2028.
- 11 Dec 2023 New trial record